ArticleAsian journal of urology2025
Clinicopathological features and prognosis of small cell carcinoma of the urinary bladder.
Article in Asian journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pyrroline-5-carboxylate reductase 1 interacts with Nudix hydrolase 5 to drive bladder cancer malignant progression via activation of the APOE/JAK2/STAT3 signalling axis.Clinical and translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the clinicopathological features and prognosis of small cell carcinoma of the urinary bladder (SCCUB). Methods: Clinicopathological data and prognosis of 24 patients with primary SCCUB treated at the Affiliated Hospital of Qingdao University (from January 2016 to December 2021) were retrospectively collected and compared with 335 patients with primary high-grade urothelial carcinoma (HG-UC) during the same period. The study endpoints were disease-free survival (DFS) and overall survival (OS). Results: Of the 24 patients with SCCUB, 19 were male and five were female. Eight (33%) cases were pure SCCUB (pSCCUB). Sixteen (67%) cases were mixed SCCUB (mSCCUB), all of which were mixed with urothelial carcinoma. All patients underwent surgery and 13 (76%, 13/17; seven patients were lost to follow-up) patients received postoperative adjuvant chemotherapy. We found no significant difference in clinicopathological features between pSCCUB and mSCCUB. However, compared to HG-UC, SCCUB had higher lymph node metastasis ( Conclusion: Compared with the common HG-UC, SCCUB is rare with specific clinicopathological features and a worse prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.